机构:[a]Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, PR China神经内科首都医科大学宣武医院[b]Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, PR China[c]Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, PR China[d]Key Neurodegenerative Laboratory of Ministry of Education of the People's Republic of China, Beijing, PR China
The missense mutation V717I in amyloid precursor protein (APP) gene has been reported in many early-onset familial Alzheimer's disease (EOFAD) families. However, no detailed clinical picture regarding this mutation has ever been described for Chinese EOFAD. We investigate the age at onset (AAO), initial clinical features and non-cognitive neurological symptoms in 34 affected subjects from five Han Chinese EOFAD families with the APPV717I mutation to characterize the clinical phenotype. The AAO was 54.7 +/- 4.9 years (n = 34), with the APOE epsilon 4 allele correlating with a decreased AAO. Prominent early affective symptoms, executive dysfunction and disorientation at onset were exhibited in 26 (76.5%), 18 (52.9%) and 16 (47%) cases, respectively. Spastic paraparesis and cerebellar ataxia occurred frequently in 13 (38.2%) and 12 (35.3%) cases, respectively, during the late stages of disease. The specific clinical phenotype of the APPV717I mutation for Chinese families is characterized by prominent early affective symptoms, executive dysfunction and disorientation as well as frequent late spastic paraparesis and cerebellar ataxia as compared to Western reports. We conclude that ethnic differences, environment or additional unknown factors may challenge the homogeneity of EOFAD with identical APP mutations. (C) 2016 Published by Elsevier B.V.
基金:
the CHINA-CANADA Joint Initiative on Alzheimer's Disease and Related Disorders (81261120571),
the Key Medical Professional Development Plan of Beijing Municipal Administration of Hospitals (ZYLX201301),
a Seed Grant of International Alliance of Translational Neuroscience (PXM2014_014226_000006),
the National Science and Technology Major Projects for “Major New Drug Innovation and Development” of the Twelfth 5-year Plan Period (2011ZX09307-001-03),
the National Key Technology R&D Program in the Eleventh Five-year Plan Period (2006BAI02B01),
the Key Project of the National Natural Science Foundation of China (30830045),
the Scientific Promoting Project of Beijing Institute for Brain Disorders (BIBDPXM2014_014226_000016).
第一作者机构:[a]Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, PR China
通讯作者:
通讯机构:[*1]Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing 100053, PR China.
推荐引用方式(GB/T 7714):
Guili Zhang,Yunyan Xie,WeiWang,et al.Clinical characterization of an APP mutation (V717I) in five Han Chinese families with early-onset Alzheimer's disease[J].JOURNAL OF THE NEUROLOGICAL SCIENCES.2017,372:379-386.doi:10.1016/j.jns.2016.10.039.
APA:
Guili Zhang,Yunyan Xie,WeiWang,Xueyan Feng&Jianping Jia.(2017).Clinical characterization of an APP mutation (V717I) in five Han Chinese families with early-onset Alzheimer's disease.JOURNAL OF THE NEUROLOGICAL SCIENCES,372,
MLA:
Guili Zhang,et al."Clinical characterization of an APP mutation (V717I) in five Han Chinese families with early-onset Alzheimer's disease".JOURNAL OF THE NEUROLOGICAL SCIENCES 372.(2017):379-386